Malik Fady Ibraham 4

4 · CYTOKINETICS INC · Filed Mar 17, 2026

AI-generated summary of this filing

Updated Mar 17, 2026

Cytokinetics (CYTK) EVP Malik Fady Ibraham Receives Equity Awards

What Happened

Malik Fady Ibraham, EVP Research & Development at Cytokinetics (CYTK), was granted annual equity awards on March 15, 2026. The filing reports 27,306 restricted stock units (RSUs) and two option awards covering 1,665 and 39,527 share-equivalents, for a combined total of 68,498 share-equivalents. All grants are reported at $0 (standard for awards) and were reported on a Form 4 filed March 17, 2026.
These were awards (not open-market purchases or sales) and are typical compensation grants rather than immediate purchases or dispositions.

Key Details

Transaction date: March 15, 2026; Form 4 filed: March 17, 2026.
Reported amounts: 27,306 RSUs; 1,665 option units (derivative); 39,527 option units (derivative). Total = 68,498 share-equivalents. Reported price/value = $0.
Shares owned after the transaction: not specified in the provided filing summary.
Footnotes: F1 — RSUs convert 1:1 to common stock and vest 40% at 1 year, 40% at 2 years, 20% at 3 years (subject to continued employment) under the 2004 Equity Incentive Plan. F2 & F3 — stock options vest in 48 equal monthly installments, subject to continued employment, under the same plan.
No indication of a 10b5-1 plan, tax withholding sale, or cashless exercise in the reported entries. Strike prices for the option grants are not included in the provided summary.

Context

The derivative entries represent option awards (rights to purchase shares subject to vesting), not exercised options or immediate sales. There is no evidence in this filing that any shares were sold or that options were exercised for cash.
Awards like RSUs and option grants are routine forms of executive compensation and do not by themselves indicate the insider’s buying or selling sentiment. The filing appears to have been submitted within the typical Form 4 reporting window.

Form 4

Period: 2026-03-15

EVP Research & Development

Transactions

Award
Common Stock
[F1]
2026-03-15+27,306→ 165,935 total
Award
Incentive Stock Option (Right to Buy)
[F2]
2026-03-15+1,665→ 1,665 total
Exercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (1,665 underlying)
Award
Non-Qualified Stock Option (Right to Buy)
[F3]
2026-03-15+39,527→ 39,527 total
Exercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (39,527 underlying)

Footnotes (3)

[F1]Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
[F2]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
[F3]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

Signature

/s/ John O. Faurescu, attorney-in-fact for Dr. Malik|2026-03-17

1 file